Statement: the primary trial records several immune system related adverse events in its patients, whereas the secondary trial does not.
Primary_evidence: Adverse Events 1:   Total: 16/30 (53.33%)   Chest pain *1/30 (3.33%)   Abdominal pain *1/30 (3.33%)   Diarrhea *2/30 (6.67%)   Edema limbs *1/30 (3.33%)   Hypersensitivity *2/30 (6.67%)   Autoimmune disorder *1/30 (3.33%)   Immune system disorder *1/30 (3.33%)   Device related infection *2/30 (6.67%)   Upper respiratory infection *1/30 (3.33%)   Fracture *1/30 (3.33%)
Secondary_evidence: Adverse Events 1:   Total: 7/52 (13.46%)   Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%)   Atrial Fibrillation * 1/52 (1.92%)   Sepsis * 1/52 (1.92%)   Muscle weakness upper limb * 1/52 (1.92%)   Dizziness * 1/52 (1.92%)   Seizure * 1/52 (1.92%)   Nervous system disorders - Other, specify *  [1]1/52 (1.92%) Adverse Events 2:   Total: 1/30 (3.33%)   Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 1/30 (3.33%)   Atrial Fibrillation * 0/30 (0.00%)   Sepsis * 0/30 (0.00%)   Muscle weakness upper limb * 0/30 (0.00%)   Dizziness * 0/30 (0.00%)   Seizure * 0/30 (0.00%)   Nervous system disorders - Other, specify *  [1]0/30 (0.00%)